Arsani William
Managing Partner and Chief Investment Officer @ Logos Capital
San Francisco, United States
Arsani William is a Series B investor at Logos Capital in San Francisco focused on Biotechnology and Medical. Dr. William serves as Managing Partner, Chief Executive Officer and Chief Investment Officer of Logos Capital. Prior to founding Logos, Dr. William was an investment professional at Farallon Capital Management, where he helped grow the development of Farallon’s biopharma portfolio. Dr. William holds an MD from Harvard Medical School, where he was aGerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Arsani William invests in
Stages Arsani William invests in
Countries Arsani William invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 2 (50%)
- Health Care 2 (50%)
- Biopharma 1 (25%)
- Life Science 1 (25%)
Stage
- Series B 2 (50%)
- Series C 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Attralus
|
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $56M / Series B / Feb 06, 2024 | |
|
Attralus
|
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $116M / Series B / Sep 08, 2021 | |
Vividion Therapeutics
|
Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s platform was spun out of the labs of Vividion’s scientific founders, a teamof experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients. | $135M / Series C / Feb 24, 2021 | |
Design Therapeutics
|
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $125M / Series B / Jan 27, 2021 |
Co-Investors
Surveyor Capital
4 deals together
Vivo Capital
3 deals together
Janus Henderson Investors
2 deals together
RA Capital Management
2 deals together
Sarissa Capital Management
2 deals together
T. Rowe Price
2 deals together
About Logos Capital
Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifyingcompelling investment ideas and uncorrelated-market returns. They combine scientific diligence with their statistical modeling of clinical trials to achieve the highest levels of conviction in each position.
Logos Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Graham Walmsley
Co-Founder and Managing Member
|
|||
|
Arsani William
Managing Partner and Chief Investment Officer
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Arsani William invest in?
Arsani William invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Arsani William?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Arsani William last invest?
The most recent investment recorded for Arsani William closed in Feb 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
